Novartis Defends $2.1 Million Gene Therapy After FDA Data Manipulation Claims—Brainstorm Health
Good afternoon, readers.
Shares of Novartis fell nearly 3% in Tuesday trading after the Food and Drug Administration (FDA) levied serious allegations of data manipulation against the drug giant. The claims involve the gene therapy Zolgensma, used to treat the devastating childhood rare disorder spinal muscular atrophy (SMA) - and which, at a $2.1 million list price, is the most expensive drug in the world.
Novartis purchased AveXis, the company that manufactures Zolgensma, in 2018, and received FDA approval for the drug last year. The FDA said on Tuesday that, "following the FDA’s approval of the product, the agency was informed by AveXis Inc., the product’s manufacturer, about a data manipulation issue that impacts the accuracy of certain data from product testing performed in animals submitted in the biologics license application (BLA) and reviewed by the FDA."
The agency didn't say that these manipulations would warrant yanking Zolgensma's approval. In fact, it said that it is "carefully assessing this situation and remains confident that Zolgensma should remain on the market. Out of the large amount of submitted information reviewed by the agency, our concerns at this time are limited to only a small portion of the product testing data that was contained in the marketing application."
Still, acting FDA Commissioner Ned Sharpless shot a clear warning across Novartis' bow. That includes the specter of potential criminal charges. "We rely on truthful scientific data to make regulatory decisions, and we take the issue of data integrity very seriously. In this case, the agency will use its full authorities to take action, if appropriate, which may include civil or criminal penalties," Sharpless wrote in a tweet.
Novartis defended the integrity of the Zolgensma application, noting that the data issues were self-reported.
"At no time during the investigation did the findings indicate issues with product safety, efficacy, or quality. We remain fully capable of releasing high-quality, fully compliant Zolgensma to patients in need. We have and will continue to work in close cooperation with the FDA to appropriately update our submission and address any quality gaps identified," the company wrote in a statement.
Read on for the day's news.
Cardiogram comes to Fossil’s smartwatch. The latest versions of Fossil’s smartwatches (the fifth generation of the devices) will come with Cardiogram Care fully unlocked, MobiHealthNews reports. Cardiogram’s app measures heart rate in order to suss out a whole bunch of cardiovascular and sleep-related conditions, including sleep apnea, diabetes, and hypertension. The pre-installed approach (rather than Cardiogram’s usual subscription model) highlights the bet that Fossil is putting on such technologies and their demand among consumers. (MobiHealthNews)
Glaxo offloads rights to experimental Ebola, Marburg vaccines to Sabin Institute. British drug giant GlaxoSmithKline is officially exiting the Ebola and Marburg virus vaccine development game, offloading the treatments to the Sabin Vaccine Institute. Three total assets (two for Ebola, which is currently ravaging the Congo, and one for Marburg) are part of the deal; Merck and Johnson & Johnson have both been developing Ebola-fighting treatments in the outbreak’s wake. (Reuters)
THE BIG PICTURE
Drug overdose deaths fell for the first time in three decades. Here’s a bit of good news – a new study finds that drug overdose deaths (including those for opioids) fell for the first time in about 30 years. One major reason? An increasing willingness to dispense the opioid overdose antidote naloxone at pharmacies. Still, health officials say there’s plenty of work left to be done. “We don’t think anybody is at the level we’d like to see them,” said Dr. Anne Schuchat of the Centers for Disease Control and Prevention (CDC) in a statement. (Fortune)
Why Cord-Cutting Hasn’t Doomed Cable Companies, by Aaron Pressman
The Power of Inclusive Language, by Claire Zillman
Investors Pick Up More Gun Stocks Following Mass Shootings, by Lucinda Shen
Find past coverage. Sign up for other Fortune newsletters.